Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 6, 2000, Pages 457-462

  Nicoletto, M O ^a   Padrini, R ^b   Galeotti, F ^a   Ferrazzi, E ^c   Cartei, G ^d   Riddi, F ^a   Palumbo, M ^b   De Paoli, M ^a   Corsini, A ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Cardiovascular Diagnosis and Endoluminal Interventions Rovigo General Hospital Rovigo   (Italy)

^d UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Hyperthermia; IPHP; Mitoxantrone; Ovarian cancer; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; MITOXANTRONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG METABOLISM; FEMALE; GYNECOLOGIC CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTHERMIC THERAPY; OVARY CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HEAT; HUMANS; INFUSIONS, PARENTERAL; MIDDLE AGED; MITOXANTRONE; OVARIAN NEOPLASMS;

EID: 0034108462     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051019     Document Type: Article

References (31)

1. 1. Alberts DS (1999) Treatment of refractory and recurrent ovarian cancer. Semin Oncol 26 [Suppl I]: 8
2. 2. Alberts DS, Surwit EA, Peng YM, et al. (1988) Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. Cancer Res 48: 5874
3. 3. Alberts DS, Liu PY, Hanningan EV, et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950
4. 4. Blochl-Daum B, Eichler HG, Rainer H, et al. (1988) Escalating dose regimen of intraperitoneal mitoxantrone: phase I study -clinical and pharmacokinetic evaluation. Eur J Cancer Clin Oncol 24: 1133
5. 5. Dufour P, Bergerat JP, Barats JC, et al. (1994) Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Cancer 73: 1865
6. 6. Elias D, Detroz B, Debaene B, et al. (1994) Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia: reliable and unreliable concepts. Hepatogastroenterology 41: 207
7. 7. Faulds D, Balfour JA, Chrisp P, Langtry HD (1991) Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 41: 400
8. 8. Fernandez-Trigo V, Stuart OA, Stephens AS, Hoover LD, Sugarbaker PH (1996) Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C. Cancer Treat Res 81: 51
9. 9. FIGO Cancer Committee (1986) Staging announcement. Gynecol Oncol 25: 383
10. 10. Formenti SC, Shrivastava PN, Saponzik M, et al. (1996) Abdomino-pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: feasibility, tolerance and pharmacology. Int J Radiat Oncol Biol Phys 35: 993
11. 11. Fujimoto S, Takahashi M, Mutou T, et al. (1997) Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 79: 884
12. 12. Gilly FN, Carry PY, Sayag AC, et al. (1994) Regional chemotherapy (with mitomycin C) and intraoperative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 41: 124
13. 13. Hahn GM (1979) Potential for therapy of drugs and hyperthermia. Cancer Res 39: 2264
14. 14. Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH (1998) Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology 55: 130
15. 15. Kober F, Heiss A, Roka R (1996) Diffuse and gross peritoneal carcinomatosis treated by intraperitoneal hyperthermic chemoperfusion. Cancer Treat Res 82: 211
16. 16. Kowal CD, Bertino JR (1979) Possible benefits of hyperthermia to chemotherapy. Cancer Res 39: 2285
17. 17. Leopold KA, Oleson JR, Clarke-Pearson D, et al. (1993) Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma. Int J Radiat Oncol Biol Phys 27: 1245
18. 18. Loggie BW, Perini M, Fleming RA, Russel GB, Geisinger K (1997) Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modalities therapy. Am Surg 63: 137
19. 19. Los G, Sminia P, Wondergem J, et al. (1991) Optimization of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 27: 472
20. 20. Markman M (1996) Intraperitoneal chemotherapy in the treatment of ovarian cancer. Ann Med 28: 293
21. 21. Markman M, George M, Hakcs T, et al. (1990) Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. J Clin Oncol 8: 146
22. 22. Markman M, Alberts D, Rubin S, et al. (1993) Evidence for persistence of mitoxantrone within the peritoneal cavity following intraperitoneal delivery. Gynecol Oncol 48: 185
23. 23. Markman M, Reichman B, Hakes T, et al. (1993) Intraperitoneal chemotherapy in the management of ovarian cancer. 71 [Suppl 4]: 1565
24. 24. Nagel JD, Varossieau FJ, Dubbelman R, Bokkel Huinink WW ten, McVie JG (1991) Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. Cancer Chemother Pharmacol 29: 480
25. 25. Nicoletto MO, Padrini R, Ferrazzi E, et al. (1993) Phase-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer. Eur J Cancer 29A: 1242
26. 26. Oza AM, Bokkel Huinink W ten, Dubbelman R, et al. (1994) Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. Ann Oncol 5: 343
27. 27. Schink JC (1999) Current initial therapy of stage III and IV ovarian cancer: challenges for managed care. Semin Oncol 26 [Suppl I]: 2
28. 28. Schneebaum S, Arnold MW, Staubus A, Young DC, Dumond D, Martin EW Jr (1996) Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Ann Surg Oncol 3: 44
29. 29. Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40: 256
30. 30. Van de Vaart PJ, Vange N van der, Zoetmulder FA, et al. (1998) Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 34: 148
31. 31. World Health Organization (1979) Handbook for reporting results of cancer treatment (Offset Publication No. 48). WHO, Geneva